GlassScriptPhysician profile
Lisa C Winterroth
NPI 1467688069
$3,536.24
in general payments reported to CMS, 2019-2025
20 companies · $1,462 in 2025
The $1,462 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.35 · 2020: $11.44 · 2021: $44.66 · 2022: $265 · 2023: $350 · 2024: $1,325 · 2025: $1,462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,916 · Honoraria: $175 · Education: $45.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,915.93 |
| Honoraria | $175.00 |
| Education | $45.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,372.63 | 2020-2025 | Fasenra, Tezspire, Airsupra |
| Genzyme Corporation | $409.54 | 2023-2025 | |
| Glaxosmithkline, LLC. | $378.26 | 2019-2025 | Nucala, Trelegy Ellipta |
| Amgen INC. | $368.22 | 2023-2025 | Tezspire |
| Aimmune Therapeutics, INC. | $193.12 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $187.75 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $165.18 | 2022-2025 | Takhzyro |
| Regeneron Healthcare Solutions, INC. | $104.93 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $54.41 | 2024-2025 | Capvaxive |
| Biocryst US Sales Co., LLC | $50.24 | 2021-2025 | Orladeyo |
| Kaleo, INC. | $37.90 | 2019-2024 | Auvi-Q |
| Greer Laboratories, INC. | $28.83 | 2025 | Oralair |
| Genentech USA, INC. | $28.33 | 2024-2025 | Xolair |
| Ionis Pharmaceuticals, INC. | $28.29 | 2025 | Dawnzera |
| Csl Behring | $26.85 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cycle Pharmaceuticals INC | $23.72 | 2024 | Sajazir |
| Organon LLC | $22.44 | 2025 | |
| Shire North American Group INC | $21.84 | 2019 | |
| Alk-Abello, INC | $17.90 | 2023 | Grastek, Odactra, Ragwitek |
| Ars Pharmaceuticals Operations, INC. | $15.86 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Winterroth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.